Latest Steatohepatitis Stories
Estimates of the prevalence of liver disease suggest that oneâ€third of the United States population has nonâ€alcoholic fatty liver disease (NAFLD).
NEW YORK, July 28 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients...
A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid (UDCA), suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis (NASH), does not improve overall histology in these patients.
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style.
NIH-funded, NEJM study is largest ever to look at nonalcoholic steatohepatitis, an obesity-related condition.
A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis (NASH), according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.
Modifying risk factors essential in controlling liver disease progression.
Encouraging results in 1 male subgroup may guide future clinical practice.
Results show highly significant dose dependent response.
Sonic detection of liver stiffness emerges as a useful screening and prognostic test.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.